Last reviewed · How we verify
NCT06730581
Utidelone Capsule Monotherapy for Patients with Advanced Solid Tumors
Phase 2 trial testing Utidelone Capsule 60mg/m2/d in Gastric Cancer Adenocarcinoma Metastatic in 100 participants. Not yet recruiting.
31 December 2026
Quick facts
| Lead sponsor | Beijing Biostar Pharmaceuticals Co., Ltd. |
|---|---|
| Phase | Phase 2 |
| Status | Not yet recruiting |
| Study type | INTERVENTIONAL |
| Allocation | non randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 100 |
| Start date | 1 December 2024 |
| Primary completion | 31 December 2026 |
| Estimated completion | 31 December 2026 |
Drugs / interventions tested
- Utidelone Capsule 60mg/m2/d — full drug profile →
- Utidelone capsule 75mg/m2 — full drug profile →
- Utidelone Capsule
Conditions studied
- Gastric Cancer Adenocarcinoma Metastatic — all drugs for Gastric Cancer Adenocarcinoma Metastatic →
- Ovarian Cancer — all drugs for Ovarian Cancer →
- Bile Duct Cancer — all drugs for Bile Duct Cancer →
Sponsor
Beijing Biostar Pharmaceuticals Co., Ltd. — full company profile →
Who can join
Adults 18 to 70, any sex, with Gastric Cancer Adenocarcinoma Metastatic or Ovarian Cancer. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This trial is an open, multicenter, phase II clinical trial to evaluate the efficacy and safety of Utidelone capsules in patients with advanced solid tumors. The target population of the study is patients with advanced solid tumors (gastric cancer, ovarian cancer, cholangiocarcinoma and other tumors (esophageal cancer, hepatocellular carcinoma, colorectal cancer, cervical cancer). The number of evaluable cases for tumor enrollment in gastric, ovarian, and bile duct cancers will be 20 cases each, and the total number of other tumors (including esophageal, liver, colorectal, and cervical cancers) will be no more than 40 cases. Patients who met the enrollment criteria received Utidelone capsule (UTD2) monotherapy.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT06730581
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Gastric Cancer Adenocarcinoma Metastatic
Currently open trials in the same condition.
- NCT06962137 — Phase II RAINSPOT: Zolbetuximab-Paclitaxel-Ramucirumab for CLDN18.2 Positive Gastro-esophageal Cancer · Phase 2 · recruiting
- NCT07392346 — Safety and Efficacy of Fruquintinib Plus Nab-Paclitaxel and Iparomlimab and Tuvonralimab Injection in the Second-Line Tr · Phase 2 · recruiting
- NCT07149090 — Lenvatinib in Combination With Nivolumab Plus Chemotherapy in Metastatic Gastric Cancer Patients With Malignant Ascites · Phase 1, PHASE2 · recruiting
- NCT06711471 — Trifluridine/tipiracil (TAS-102), Bevacizumab, and Camrelizumab As Third-line or Later-line Therapy of Gastric Cancer · Phase 2 · recruiting
- NCT06702683 — The Correlation Between Blood Concentration of Sintilimab and Efficacy and Adverse Reactions in Patients with Advanced G · recruiting
Other Beijing Biostar Pharmaceuticals Co., Ltd. trials
Trials by the same sponsor.
- NCT06841679 — Utidelone Capsule Combined With Fluoropyrimidine- and Platinum-containing Therapy in First-line Treatment of Patients Wi · Phase 2, PHASE3 · recruiting
- NCT06683703 — Utidelone Injection Combined with Bevacizumab Injection for Non-small Cell Lung Cancer Patients with Brain Metastases · Phase 2 · not yet recruiting
- NCT05700084 — Tolerability and Bioavailability of Utidelone Capsule in Patients With Advanced Solid Tumors · Phase 1 · recruiting
- NCT05673629 — Utidelone in Combination With AC Versus Docetaxel in Combination With AC for Neoadjuvant Chemotherapy in Patients With H · Phase 3 · unknown
- NCT05673590 — Utidelone Versus Docetaxel in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer · Phase 3 · unknown
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06730581 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Beijing Biostar Pharmaceuticals Co., Ltd.
- Last refreshed: 12 December 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06730581.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing